Sandbox
When a pharmaceutical product test result falls outside the registered specifications, it is classified as Out of Specification (OOS). Regulators (such as the FDA and EMA) require a formal, documented investigation to determine if the result is a laboratory error or a true product failure. This article details the steps of a compliant OOS investigation.
Phase I: Laboratory Investigation
The investigation must begin immediately in the laboratory, before any sample is discarded. The analyst and supervisor must assess:
- Standard preparation and instrument calibration.
- Reagent freshness and preparation logs.
- Calculations and raw data entry errors.
- Glassware cleanliness and contamination checks.
If a clear laboratory error is identified, the original test result is invalidated, the error is documented, and a re-test is performed. If no laboratory error is found, the investigation proceeds to Phase II.
Phase II: Full-Scale Manufacturing Investigation
Phase II shifts the focus to the production facility to determine if manufacturing deviations caused the issue. This involves reviewing batch production records, environmental monitoring logs, equipment performance, and raw material COAs.
Implementing Corrective and Preventive Actions (CAPA)
Once the root cause is identified, the quality unit must establish a CAPA plan. Corrective actions address the immediate issue (e.g., discarding the affected batch), while Preventive actions modify processes, training, or equipment to ensure the error does not happen again.
